Specialty distribution and provider platforms drove September-quarter profit gains at the Big Three as brand pricing weighed on results.
|Articles|June 14, 2021
Construction of Yposkesi’s second commercial bioproduction site is underway
Project SKY features one of Europe’s largest facilities for advanced therapies, says CDMO
Advertisement
Yposkesi, a contract development and manufacturing organization (CDMO) that specializes in cell and gene therapies, has launched project SKY, the construction of Yposkesi’s second commercial cell and gene therapy facility; it is meant to be a resource for drug developers of biologics, also known as ATMPs (advanced therapy medicinal products). ATMPs treat patients living with rare and life-threatening diseases.
In March, Yposkesi welcomed SK Pharmteco, another CDMO, as a new majority equity shareholder in its company. Backed by SK Pharmteco, Yposkesi is investing approximately $71 million into the new 50,000 square-foot France site, making it one of the largest ATMP facilities in Europe, according to the company. Project SKY is expected to create 80 new jobs by 2023.
The new building will be home to two additional production lines with several 1000L scale bioreactors.
Advertisement
Related to this article
In this week's Pharma Pulse, Cencora agrees to acquire American Oncology Network, five major employers back electronic prior authorization for self-funded health plans and FDA finalizes its guidance on prescription drug apps and software.
Bob Cochran, former senior director, trade relations at Incyte, discusses direct-to-patient models, specialty launches and distribution strategy.
A CMS final rule codifies Medicare drug price negotiation from 2029, adds a fixed combination drug policy and implements a small biotech price floor.
Generative AI has made pharma teams faster, but real value depends on redesigning commercialization workflows, especially as agentic AI raises the governance stakes.
Siloed pricing, contracting and affordability decisions can undercut a launch. IQVIA experts explain how system-level modeling surfaces trade-offs early.
Nuvera’s PURE Engagement research, built on feedback from more than 2,300 physicians and support staff, ranks 2026 patient support leaders by company size and therapeutic area.
In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean for its launch strategies and an ACTO survey finds most life sciences leaders see no clear industry standard for responsible AI.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
How CMS’ Final Negotiation Rule Treats New Drug Formulations
2
Bob Cochran: Direct-to-Patient Was a 'Watershed Moment' for Commercial Trade
3
Pharma Pulse: CVS Health to Break in Two, Bayer Weighs MFN
4
Big Three Distributors Lean on Specialty for Profit Growth
5